ClinicalTrials.Veeva

Menu
B

Barbara Ann Karmanos Cancer Institute | Detroit, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Docetaxel
cisplatin
Gemcitabine
cyclophosphamide
Paclitaxel
paclitaxel
Cisplatin
carboplatin
etoposide
Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

64 of 589 total trials

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

Enrolling
Neoplasms
Neoplasm Metastasis
Drug: EMB-01

This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and prelimi...

Enrolling
Locally Advanced or Metastatic Solid Tumors
Drug: LUNA18
Drug: Cetuximab

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-c...

Enrolling
Multiple Myeloma
Drug: Cilta-cel

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling
Advanced Solid Tumors
Drug: RO7623066
Drug: Olaparib

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting
Kidney Cancer
RCC
Drug: MK-3795
Drug: Nivolumab

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patient...

Enrolling
Head and Neck Squamous Cell Carcinoma
Drug: Petosemtamab
Drug: Investigator's Choice

To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chem...

Enrolling
Chemotherapy-induced Peripheral Neuropathy
Chemotherapy-induced Neuropathic Pain
Drug: Placebo
Drug: Tetrodotoxin

The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in par...

Enrolling
Hepatocellular Carcinoma
Drug: Atezolizumab
Drug: Bevacizumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Emactuzumab
Drug: Niraparib

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (pat...

Active, not recruiting
Colorectal Neoplasms
Drug: Ipilimumab
Drug: Atezolizumab

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: Axatilimab

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiatio...

Enrolling
Solid Tumor, Adult
Drug: BGB-24714
Drug: Paclitaxel

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administ...

Enrolling
Metastatic Cancer
Solid Tumor
Biological: CF33-hNIS
Biological: Pembrolizumab

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple my...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Cilta-cel

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advan...

Active, not recruiting
Solid Tumor
Colorectal Adenocarcinoma
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimen...

Enrolling
Amyloidosis
Drug: Dexamethasone
Drug: Cyclophosphamide

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and...

Enrolling
Solid Tumors
Drug: Nivolumab
Drug: DF6002

This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: DS-9606a

Trial sponsors

B
SWOG Cancer Research Network logo
R
G
C
National Cancer Institute (NCI) logo
Janssen (J&J Innovative Medicine) logo
Alliance for Clinical Trials in Oncology logo
E
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems